Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2019 Jan 1;5(1):111.
doi: 10.1001/jamaoncol.2018.5102.

Competing Risks for a Diagnosis of Invasive Breast Cancer-Reply

Adam R Brentnall  1 , Diana S M Buist  2 , Jack Cuzick  1
Affiliations
Comment

Competing Risks for a Diagnosis of Invasive Breast Cancer-Reply

Adam R Brentnall et al. JAMA Oncol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Drs Cuzick and Brentnall report receiving royalty payments through Cancer Research UK for commercial use of the Tyrer-Cuzick algorithm. No other disclosures are reported.

Comment on

References

    1. Brentnall AR, Cuzick J, Buist DSM, Bowles EJA. Long-term accuracy of breast cancer risk assessment combining classic risk factors and breast density. JAMA Oncol. 2018;4(9):e180174. doi: 10.1001/jamaoncol.2018.0174. - DOI - PMC - PubMed
    1. Drescher CW, Beatty JDR, Resta R, et al. The effect of referral for genetic counseling on genetic testing and surgical prevention in women at high risk for ovarian cancer: results from a randomized controlled trial. Cancer. 2016;122(2):3509–3518. doi: 10.1002/cncr.30190. - DOI - PMC - PubMed
    1. Pocobelli G, Chubak J, Hanson N, et al. Prophylactic oophorectomy rates in relation to a guideline update on referral to genetic counseling. Gynecol Oncol. 2012;126(2):229–235. doi: 10.1016/j.ygyno.2012.04.046. - DOI - PMC - PubMed
    1. Manchanda R, Patel S, Gordeev VS, et al. Cost-effectiveness of population-based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 mutation testing in unselected general population women. J Natl Cancer Inst. 2018;110(7):714–725. doi: 10.1093/jnci/djx265. - DOI - PubMed
    1. Waters EA, McNeel TS, Stevens WM, Freedman AN. Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010. Breast Cancer Res Treat. 2012;134(2):875–880. doi: 10.1007/s10549-012-2089-2. - DOI - PMC - PubMed